Cardiology (all articles)
#ESCCongress – RCT: Finerenone reduced CV events in patients with kidney disease and type 2 diabetes (12.4% vs. 14.2% during a median follow-up of 3.4 years), but the risk of hyperkalemia was increased (10.8% vs. 5.3%).
29 Aug, 2021 | 18:14h | UTCNews release: Finerenone benefits patients with diabetes across spectrum of kidney disease – European Society of Cardiology
Commentaries:
Related:
Commentary on Twitter
FIGARO-DKD: Among patients with stage 1 to 4 CKD and T2 diabetes, finerenone improved CV outcomes as compared with placebo. #ESCCongress https://t.co/mcfmvftBvy pic.twitter.com/qizit80NBa
— NEJM (@NEJM) August 28, 2021
#ESCCongress – RCT: Initial hypertension treatment with a single pill with 4 drugs at quarter doses (irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) achieved better BP lowering vs. standard monotherapy (irbesartan 150 mg).
29 Aug, 2021 | 18:11h | UTCInitial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary: Quadruple UltrA-low-dose tReaTment for hypErTension – QUARTET – American College of Cardiology
#ESCCongress – RCT: Among asymptomatic patients with severe carotid stenosis, carotid surgery and stenting carry similar risks, and the long-term risk of stroke was comparable. There was no medically treated arm in this study.
29 Aug, 2021 | 18:06h | UTC
Commentary on Twitter
#ACST-2 stent CAS 🆚surgery CEA
For asymptotic carotid stenosis >= 60%https://t.co/lyLBn8C8cv
🔺No difference in death 30d MI, stroke 5 yr f/u
🔺Slight ⬆️in minor 30d strokes w Stenting but no QOL change at 6 mo
🔺no medical Rx arm
🔺both arms 1% procedural risk #ESCCongress pic.twitter.com/8ptcrstn0D— Ritu Thamman MD (@iamritu) August 29, 2021
#ESCCongress – RCT: Small benefit from systematic screening for atrial fibrillation in older adults – After a median follow-up of 6.9 y there were fewer events (stroke, embolism, bleeding, and death) in the intervention group (31·9%) vs. control group (33·0%).
29 Aug, 2021 | 18:08h | UTCClinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial – The Lancet (link to abstract – $ for full-text)
News release: Screening for atrial fibrillation could reduce risk of stroke – Karolinska Institutet
#ESCCongress – RCT: In patients with heart failure, hemodynamic-guided management was not associated with improved outcomes.
29 Aug, 2021 | 18:03h | UTCHaemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial – The Lancet (free registration required)
Commentary:
Haemodynamic-GUIDEed management of Heart Failure – GUIDE-HF – American College of Cardiology
Commentary on Twitter
The GUIDE-HF trial showed hemodynamic-guided management using remote pulmonary artery pressure monitoring didn't ⬇️ mortality & total #heartfailure events in patients regardless of HF symptom severity compared w/ patients receiving usual care: https://t.co/15Iv1N78sJ #ESCCongress pic.twitter.com/rZSNCfw4kq
— American College of Cardiology (@ACCinTouch) August 27, 2021
#ESCCongress – Pilot study in Sweden showed drones delivered defibrillators faster than ambulances to patients with suspected cardiac arrest.
29 Aug, 2021 | 18:02h | UTCEditorial: Automated external defibrillator delivery by drones: are we ready for prime time?
News releases:
Drones delivered defibrillators to patients with suspected cardiac arrests – Karolinska Institutet
Commentary on Twitter
Just released: #drones are effective in successfully delivering #AEDs to patients with suspected out-of-hospital cardiac arrest #OHCA, with a time benefit compared to emergency medical services https://t.co/D9XOI0Pep4 #EHJ #ESCcongress #ESCYoung @ehj_ed @rladeiraslopes pic.twitter.com/oRSMdQVqAC
— European Society of Cardiology Journals (@ESC_Journals) August 27, 2021
#ESCCongress [not published yet] – Systematic FFR has no additional benefit at diagnostic angiography in patients with chest pain.
29 Aug, 2021 | 18:00h | UTCPress release: Systematic pressure wire assessment has no additional benefit at diagnostic angiography – European Society of Cardiology
Commentaries:
FFR During Angiogram Not Beneficial in Chest Pain Patients: RIPCORD 2 – TCTMD
Related:
Randomized Trial: Five-Year Outcomes with PCI Guided by FFR
New WHO Guideline for the pharmacological treatment of hypertension in adults.
26 Aug, 2021 | 08:57h | UTCGuideline for the pharmacological treatment of hypertension in adults – World Health Organization
Commentary on Twitter (thread – click for more)
The number of adults aged 30-79 living with #hypertension has doubled from 650 million to 1.28 billion since 1990, according to a 🆕 comprehensive global 🌎🌍🌏 analysis of trends in hypertension prevalence, detection, treatment and control.
👉 https://t.co/MI48CX2kEO pic.twitter.com/ARpS8uipeY
— World Health Organization (WHO) (@WHO) August 25, 2021
WHO: More than 700 million people with untreated hypertension – Number of people living with hypertension has doubled to 1.28 billion since 1990.
26 Aug, 2021 | 08:54h | UTCMore than 700 million people with untreated hypertension – World Health Organization
Commentary on Twitter (thread – click for more)
The number of adults aged 30-79 living with #hypertension has doubled from 650 million to 1.28 billion since 1990, according to a 🆕 comprehensive global 🌎🌍🌏 analysis of trends in hypertension prevalence, detection, treatment and control.
👉 https://t.co/MI48CX2kEO pic.twitter.com/ARpS8uipeY
— World Health Organization (WHO) (@WHO) August 25, 2021
M-A of randomized trials: Effectiveness of the modified Valsalva maneuver in adults with supraventricular – “The meta-analysis demonstrated a significantly higher success rate for reconversion to sinus rhythm when using the modified VM compared to the standard VM in patients with an SVT (odds ratio = 4.36; 95% confidence interval, 3.30–5.76; P < 0.001)”.
26 Aug, 2021 | 08:51h | UTCEffectiveness of the modified Valsalva manoeuvre in adults with supraventricular tachycardia: a systematic review and meta-analysis – European Journal of Emergency Medicine (link to abstract – $ for full-text)
Related: Randomized Trial: Standard Valsalva vs. Modified Valsalva for Cardioversion of SVT (studies and commentaries on the subject)
Video: Modified Valsalva manoeuvre for supraventricular tachycardia – The Lancet
International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines.
26 Aug, 2021 | 08:52h | UTC
Study commentary: No blossom for fractional flow reserve in FLOWER-MI.
26 Aug, 2021 | 08:43h | UTCNo blossom for fractional flow reserve in FLOWER-MI – European Heart Journal
Expert analysis: Ideal Aspirin Dose for Secondary Prevention in Patients with ASCVD – “A lower-dose aspirin strategy is best for most patients with ASCVD given similar effectiveness, bleeding risk, and overall better adherence”.
26 Aug, 2021 | 08:42h | UTCIdeal Aspirin Dose for Secondary Prevention in Patients With ASCVD – American College of Cardiology
Top Pearls from ACC Care of the Athletic Heart 2021 Virtual.
26 Aug, 2021 | 08:36h | UTCTop Pearls from ACC Care of the Athletic Heart 2021 Virtual – American College of Cardiology
Related:
Brazilian Guidelines for Sports and Exercise Cardiology
Canadian Position Statement on the Cardiovascular Screening of Competitive Athletes
The Female Athlete’s Heart: Facts and Fallacies
Expert Analysis: The Heart of the Female Athlete
Research: Sudden Cardiac Arrest during Participation in Competitive Sports
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.
25 Aug, 2021 | 08:56h | UTCCommentary: Global and national high blood pressure burden and control – The Lancet (free registration required)
Commentary on Twitter
Our new analysis within #NCDRisC on the #worldwide #hypertension #prevalence in last 30 yrs published in @TheLancet. The number of people with HTN doubled from 1990 with 626 million🕴️♀️ and 652 million 🕴️ in 2019. Control rates were ⬇️10% in some countries!https://t.co/FdjusD38X3 pic.twitter.com/famYphfqC8
— Maciej Banach (@maciejbanach) August 25, 2021
RCT: Catheter-based adrenal ablation remits primary aldosteronism.
25 Aug, 2021 | 08:52h | UTCCatheter-Based Adrenal Ablation Remits Primary Aldosteronism: A Randomized Medication-Controlled Trial – Circulation (free for a limited period)
Commentary on Twitter
#ResearchLetter: RCT data show catheter-based adrenal ablation effectively ⬇️ BP in primary aldosteronism comparable to spironolactone – A potential therapy for patients unable to tolerate medications? https://t.co/ImSAdnVtxE #AHAJournals pic.twitter.com/WSJjFpzKPo
— Circulation (@CircAHA) August 21, 2021
Guide to Statistics and Methods: Interpreting the ACC/AHA clinical practice guideline recommendation classification system.
25 Aug, 2021 | 08:46h | UTCInterpreting the ACC/AHA Clinical Practice Guideline Recommendation Classification System – JAMA (free for a limited period)
Review: Cryoballoon ablation as initial treatment for atrial fibrillation.
25 Aug, 2021 | 08:36h | UTCRelated:
Commentary on Twitter (thread – click for more)
Please see our Stare of the Art review in @JACCJournals regarding the role of first line cryoballoon ablation versus AAD therapy.
We explore the effect if first-line ablation on arrhythmia recurrence, QOL, and healthcare utilisation. @omwazni @UBCDoM https://t.co/70IAbxt1af
— Jason Andrade (@DrJasonAndrade) August 23, 2021
Digital transformation of major scientific meetings induced by the COVID-19 pandemic: insights from the ESC 2020 annual congress.
25 Aug, 2021 | 08:35h | UTC
Commentary on Twitter
One of the COVID-19 induced challenges: How to run a major scientific online meeting as the annual European Society of Cardiology congress with >125.000 registrants?! Read all about it in EHJ – Digital Health https://t.co/Zv2pu6vv5n@escardio @ProfMartinCowie @rafavidalperez pic.twitter.com/utgsebYMoB
— Nico Bruining EiC EHJ Digital Health (@BruiningNico) August 23, 2021
RCT: SGLT2 inhibition reduces the risk of hyperkalemia in patients with diabetes and chronic kidney disease.
24 Aug, 2021 | 08:57h | UTCEffects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial – European Heart Journal (link to abstract – $ for full-text)
Commentary on Twitter
SGLT2 inhibition reduces the risk of serious hyperkalemia in people with diabetic kidney disease, which may enable greater use of RAAS inhibitors in CKD and/or heart failure
New CREDENCE data presented this week at #ESCCongress, now in @ESC_Journals:https://t.co/OEqnXTdBDi pic.twitter.com/zsanEFZVCy
— Brendon Neuen (@brendonneuen) August 23, 2021
Review: A pragmatic approach to weaning temporary mechanical circulatory support.
24 Aug, 2021 | 08:47h | UTC
Commentary on Twitter
⚠️ A Pragmatic Approach to Weaning Temporary Mechanical Circulatory Support
📌 A State-of-the-Art Review ‼️ in @JACCJournals @secardiologia @AgudosSEC @SACardiologia @JuanFDelgado1 @Dr_Manito @MartaCoboMarcos @MartaFarrero https://t.co/R2vqHwBcfi pic.twitter.com/AraH7AUMu5
— Javier Torres (@JTLLERGO) August 11, 2021
NICE Guideline: Obstructive sleep apnea/hypopnea syndrome and obesity hypoventilation syndrome in over 16s.
22 Aug, 2021 | 23:10h | UTC
M-A: GLP-1 receptor agonists reduce major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes.
22 Aug, 2021 | 22:50h | UTCCardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
M-A: The role of SGLT2 inhibitors in heart failure.
22 Aug, 2021 | 22:46h | UTCRelated:
ESC Position Paper: Cardiac, renal, and metabolic effects of SGLT2 inhibitors.
Summary: SGLT2 inhibitors and GLP-1 receptor agonists established and emerging indications.
Post-Covid-19 Tachycardia Syndrome: A distinct phenotype of Post-acute Covid-19 Syndrome.
20 Aug, 2021 | 09:51h | UTC
Commentary on Twitter
Post-COVID19 tachycardia syndrome(s): nice proposal for phenotypeshttps://t.co/XI75HCGYUH pic.twitter.com/yg303QXd1E
— Otavio Ranzani (@otavio_ranzani) August 18, 2021